Download MendeleyIdentification of a series of tricyclic natural products as potent broad spectrum inhibitors of metallo-beta-lactamases
Payne, D.J., Hueso-Rodriguez, J.A., Boyd, H., Concha, N.O., Janson, C.A., Gilpin, M., Bateson, J.H., Chever, C., Niconovich, N.L., Pearson, S., Rittenhouse, S., Tew, D., Diez, E., Perez, P., de la Fuente, J., Rees, M., Rivera-Sagredo, A.(2002) Antimicrob Agents Chemother 46: 1880-1886
- PubMed: 12019104 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1128/AAC.46.6.1880-1886.2002
- Primary Citation Related Structures:
1HLK, 1KR3 - PubMed Abstract:
This work describes the discovery and characterization of a novel series of tricyclic natural product-derived metallo-beta-lactamase inhibitors. Natural product screening of the Bacillus cereus II enzyme identified an extract from a strain of Chaetomium funicola with inhibitory activity against metallo-beta-lactamases. SB236050, SB238569, and SB236049 were successfully extracted and purified from this extract. The most active of these compounds was SB238569, which possessed K(i) values of 79, 17, and 3.4 microM for the Bacillus cereus II, Pseudomonas aeruginosa IMP-1, and Bacteroides fragilis CfiA metallo-beta-lactamases, respectively, yet none of the compounds exhibited any inhibitory activity against the Stenotrophomonas maltophilia L-1 metallo-beta-lactamase (50% inhibitory concentration > 1,000 microM). The lack of activity against angiotensin-converting enzyme and serine beta-lactamases demonstrated the selective nature of these compounds. The crystal structure of SB236050 complexed in the active site of CfiA has been obtained to a resolution of 2.5 A. SB236050 exhibits key polar interactions with Lys184, Asn193, and His162 and a stacking interaction with the indole ring of Trp49 in the flap, which is in the closed conformation over the active site groove. SB236050 and SB238569 also demonstrate good antibacterial synergy with meropenem. Eight micrograms of SB236050 per ml gave rise to an eightfold drop in the MIC of meropenem for two clinical isolates of B. fragilis producing CfiA, making these strains sensitive to meropenem (MIC < or = 4 microg/ml). Consequently, this series of metallo-beta-lactamase inhibitors exhibit the most promising antibacterial synergy activity so far observed against organisms producing metallo-beta-lactamases.
- Microbial, Musculoskeletal and Proliferative Diseases CEDD (UP1345), GlaxoSmithKline, Collegeville, Pennsylvania 19426-0989, USA. David_J_Payne@sbphrd.com
Organizational Affiliation:
